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INTRODUCTION
Chronic myeloid leukemia (CML) is characterized by the
continuous proliferation and abnormal circulation of malig-
nant hematopoietic progenitors (1). Effective purging agents
used in autologous transplantation in CML must be not only
the most specific to leukemic cells but also be the least toxic
to normal stem cells (2). Unfortunately, a potential obstacle
of autotransplantation for CML is the ineffective removal of
residual tumor cells. Various techniques have been devised
for tumor cell purging. Until now, the most commonly used
purging agents in CML have been 4-hydroperoxycyclophos-
phamide, mafosfamide and interferon- (INF- ). However,
complete cytogenetic remission rate of the agents is low,
approximately from 20% to 40% (2).
Antisense oligodeoxyribonucleotides (AS-ODNs), com-
plementary strands of small segments of mRNA, work at
the genetic level to interrupt the process by which disease-
causing proteins are produced (1). Bcr-abl AS-ODNs have
provided evidence of antileukemic effects against Philadel-
phia chromosome-positive cells. The Philadelphia chromo-
some creates bcr-abl fusion genes, which encode two abnor-
mal mRNAs, b3a2 and b2a2 (3).
Each antisense drug is designed to bind to a specific se-
quence of nucleotides in its mRNA target in order to inhibit
production of the protein encoded by the target mRNA. How-
ever there are large differences in antitumor effects observed
among AS-ODNs for the same oncogene according to the
size, chemical structure, and special treatment for enhanced
permeability (4).
We therefore aimed to develop effective purging agents for
use in autotransplantation in CML. We ventured to find meth-
ods to increase intracellular uptake of AS-ODNs. We studied
the purging effects of various kinds of the AS-ODNs according
to their length, chemical structure, breakpoint specific or not
specific, and special treatment for enhanced permeability
such as streptolysin-O (SL-O) and lipofectin. We also com-
pared the in vitro sensitivities of AS-ODNs with those of
INF- using MTT assay, clonogenic activities, and RT-PCR.
MATERIALS AND METHODS
Materials
The human bcr-abl containing CML cell line, K562 cell
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Myeloablative Treatment Supported by Autologous Stem Cell Infusion
with Neuroblastoma
Bcr-abl antisense oligodeoxynucleotides (AS-ODNs) have provided evidence of
an antileukemia effect when tested in vitro against Philadelphia-positive cells. In
order to investigate the efficacy of AS-ODNs as purging agents in chronic myeloid
leukemia (CML) patients, K562 cells, a human CML cell line, were treated in vitro
with various types of AS-ODNs and interferon- . Cells were treated in vitro for 0
and 36 hr with 40  g/mL of AS-ODNs, respectively, and incubated at 37℃ for
36 hr. Cytotoxic effects were measured by counting the number of viable cells
as well as by MTT test. Clonogenic activities were evaluated by methylcellulose
culture for 2 weeks. The effects of purging agents on the rearrangement of bcr-abl
gene were evaluated by RT-PCR. AS-ODNs inhibited the proliferation of K562
cells with time in cell count assay and MTT test. AS-ODNs were superior to INF-
in inhibiting clonogenic activity (recovery rate; 26.3% vs 64.0%). After incubation
with bcr-abl AS-ODNs primers and mRNA isolated from K562 cells, positive bands
were abolished, especially of b3a2 type and phosphorothioate type. Our results
suggest that AS-ODNs mediated purging may be one of the efficient methods
and that autograft may be an alternative treatment for allograft in high-risk group
patients of CML if they do not have a stem cell donor. 
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(Manassas, VA, U.S.A.). K562 CML cells are commonly used
for investigating purging effects because the AS-ONDs used
in the experiments were derived from antisense sequences
directed at the CML-related bcr-abl oncogene. The break-
point of the bcr-abl oncogene in K562 cell is b3a2.
ODN structure and INF-
AS-ODNs were purchased from Bioneer (Okchun, Korea).
All AS-ODNs were 18-mers or 24-mers spanning either the
b3a2 or the b2a2 bcr-abl fusion breakpoint (Table 1). In addi-
tion to AS-ODNs specific to the breakpoint, two to four
nucleotides substituted missense ODNs were also studied.
All AS-ODNs but two were phosphodiester-linked structure
(PO), and the two AS-ODNs were phosphorothioate-linked
(PS).
K562 cells (105) were seeded into a 24-well cell culture
plate in RPMI-1640 (Gibco BRL, Gaithersburg, U.S.A.)
medium supplemented with 10% fetal bovine serum (FBS).
The cells were incubated with 40  g/mL of each AS-ODN
at the start of the culture period and the same dose was added
to the medium 24, 48, and 72 hr. The control groups were
incubated in the same condition in the absence of AS-ODNs.
INF- was incubated at a concentration of either 300,000
U/mL or 30,000 U/mL. At intervals, part of the nonadhesive
cells was harvested and the viable cell number was determined
by trypan blue elusion test, then used for the next experiment.
Flow cytometric analysis for intracellular uptake of
AS-ODN
A total of 1.5×106 cells in 60  L of RPMI/FBS were incu-
bated with 40  g/mL FITC-labeled b3a2 AS-ODN at 37℃
for up to 6 hr. Ten  L aliquots were removed at 0, 1, 2, 4,
and 5 hr into 1 mL of RPMI/FBS containing 10  g/mL pro-
pidium iodide at 4℃ for 10 min and washed three times in
RPMI/FBS. 
Fluorescence was measured on a FACStar plus (Becton
Dickinson Immunocytometry systems, San Jose, CA, U.S.A.)
and uptake was recorded as the mean fluorescence intensity
(MFI).
The permeabilization enhancing techniques using SL-O
was essentially that of Barry et al. (5). Briefly, after washing
in serum-free RPMI medium, 1.5×106 K562 cells were
exposed to dithiothreitol (DTT)-activated SL-O at 1,000
IU/mL or 100 IU/mL concentration at 37℃. Thirty minutes
later, cells were washed with RPMI/FBS twice and used for
flow cytometric analysis as previously mentioned.
We also used the liposome formation technique to enhance
permeabilization. FITC-labeled AS-ODNs and lipofectin
(Gibco BRL, Gaitherburg, U.S.A.) were mixed for 15 min
at 37℃, using sufficient AS-ODNs to achieve a final con-
centration of 2  mol/L after addition to the cell suspensions.
1.5×106 K562 cells were suspended in 200  L RPMI/FBS
and incubated with AS-ODN/lipofectin mixture for 15 min
at 37℃. Subsequently, the intracellular uptake of this mix-
ture was analyzed by FACS. No attempt was made to remove
the lipofectin.
MTT assay
Thirty thousand cells pretreated with AS-ODNs or IFN-
were seeded into a 96-well cell culture plate in 200  L RPMI/
FBS. Two  g/mL MTT [3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide; Sigma, St Louis, MO, U.S.A.]
solubilized in 0.15 M PBS was added and incubated for 4 hr
at 37℃. After solubilizing the formazan with 100  L 0.04N
HCl-isopropanol, the absorbance at 540 nm was measured
by using a microplate reader (Molecular Devices, Gaither-
burg, U.S.A.).
Colony-forming unit for culture (CFU-C) 
CFU-C assays were performed using a complete methyl-
cellulose medium with recombinant cytokines for colony
assays of human cells (Methocult GF-H4434; StemCell Tech-
nologies, Vancouver, BC, Canada). It contains 1.0% methyl-
cellulose, 30% fetal bovine serum, 1% BSA, 10  M 2-mer-
captoethanol, 2 mM L-glutamine, 10 ng/mL recombinant
human (rh) interleukin-3, 10 ng/mL rh granulocyte-mono-
cyte colony stimulating factor, 50 ng/mL rh stem cell factor,
3 units/mL rh erythopoietin in Iscove’s Modified Dulbecco’s
medium (IMDM; GibcoBRL, Gaithersburg, MD, U.S.A.).
MNCs (2×105) were resuspended in plastic 35 mm tis-
sue culture dishes containing 1 mL methylcellulose medium
and cultured at 37℃ in 100% humidified 5% CO2 in air.
After 2 weeks, CFU-Cs were counted according to color, size,
and marginal shape.
Reverse transcription polymerase chain reaction (RT-
PCR) analysis
Total RNAs were extracted by acid-guanidinium phenol
chloroform method using RNAzol B (TEL-TEST, Friends-
wood, U.S.A.).
Two  g RNAs were reverse transcribed in a mixture of 1×
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18-mers
b3a2 antisense   5′ -GAA-GGG-CTT-TTG-AAC-TCT-3′
B3a2 missense(TAT) 5′ -GAA-GTG-CTG-TTG-CAC-TAT-3′
b3a2 missense   5′ -GAA-GTG-CTG-TTG-CAC-TAT-3′
b2a2 antisense   5′ -GAA-GGG-CTT-CTT-CCT-TAT-3′
b2a2 missense   5′ -GAA-CGG-CAT-CTA-CGT-TAT-3′
24-mers
b3a2 antisense   5′ -GCT-GAA-GGG-CTT-TTG-AAC-TCT-GCT-3′
b2a2 antisense   5′ -GCT-GAA-GGG-CTT-CTT-CCT-TAT-TGA-3′
Table 1. AS-ODN sequence usedRT buffer [50 mM Tris-HCl (pH 8.3), 75 mM KCl, 10 mM
DTT, 3 mM MgCl2], 1  M oligo dT primer (Pharmacia,
Uppsala, Sweden), 100 U Moloney murine leukemia virus
reverse transcriptase (Gibco BRL, Gaithersburg, U.S.A.),
0.5 mM each dNTPs (Boehringer Mannheim, Germany),
and 20 U RNase inhibitor (Boehringer Mannheim) at 37℃
for 90 min.
For the detection of bcr-abl mRNA, 200 ng cDNA was
amplified in a mixture of 1×Taq DNA polymerase buffer
[20 mM Tris-HCl (pH 7.5), 100 mM KCl, 1 mM DTT,
0.1 mM EDTA, 0.5% Tween-20, 0.5% Nonidet P40, 50%
glycerol, 1.5 mM MgCl2], 1U Taq DNA polymerase, 250
M each dNTPs, and 250 nM each primers for 30 cycles of
1 min denaturation at 94℃, 1 min annealing at 61℃, and
2 min extension at 72℃. For the nested PCR, another 30
cycles at 68℃ annealing temperature was added. In order to
verify the quantity of mRNA in each sample,  -actin
mRNA was also amplified to the same concentration for 35
cycles of 1 min denaturation at 94℃, 1 min annealing at
65℃, and 2 min extension at 72℃. After confirming bcr-abl
mRNA expression, the amount of expression was measured
by densitometer (GS-700; BioRad, Hercules, CA, U.S.A.)
The primer sequences used were as follows (Table 1); for
bcr-abl, 5′ -GAAGTGTTTCAGAAG CTT CTCC-3′ (outer
sense; B1), 5′ -TGATTATAGCCTAAGACCCGGA-3′ (outer
antisense; A3), 5′ -TGGAGCTGCAGATGCTGACCAAC-
TCG-3′ (inner sense; B2), 5′ -ATCTCCACTGGC CACAA-
AATCATACA-3′ (inner antisense; A4), for  -actin, 5′ -GT-
GGGGCGCCCCA GGCACCA-3′ (sense), 5′ -GTCCTTA-
ATGTCACGCACGATTTC-3′ (antisense).
Statistical Analysis 
Data were represented by mean±SD. A two-group com-
parison was based on a 2-tailed paired sample t test. A pvalue
<0.05 was considered statistically significant.
RESULTS
FACS analysis for the detection of AS-ODNs uptake
The frequency distribution of fluorescent AS-ODNs into
K562 cells was compared to various purging agents. 
Fig. 1 illustrates the AS-ODNs uptake into K562 CML
cells exposed continuously to b3a2-directed ODN of various
treatments for 5 hr. The uptake is expressed as the mean flu-
orescence intensity (MFI) of fluorescein-labeled AS-ODNs
per cell (Fig. 1A). AS-ODNs uptakes increased sharply with
time to 1 hr following incubation and then maintained a
plateau until 5 hr in all groups. There were no differences in
AS-ODNs uptake between the simple diffusion group and
the SL-O treatment group. Additionally, no differences were
seen in the concentration of SL-O. Transfection by lipofectin
treatments was more efficient than the other groups in intra-
cellular uptake of AS-ODNs (p<0.05) (Fig. 1B).
Cytotoxic effects of various types of purging agents
measured by cell count assay 
Cell numbers were increased until 72 hr and then decreased
in untreated control group. The cytotoxic effects of AS-ODNs
groups were superior to those of INF- groups at 48 hr, 72
hr, and 96 hr (p<0.05). AS-ODNs groups were examined
for their cytotoxic effects, divided into three aspects accord-
ing to the breakpoint specific or not specific for target gene,
chemical structure linked to PO or PS form, and the length
of AS-ODNs for 18－ or 24－mers. The purging effects of
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Fig. 1. Antisense oligodeoxyribonucleotides (AS-ODN) uptakes over a 5-hr incubation period. (A) Representative histogram of intracellar
uptake of FITC-labeled AS-ODNs with simple diffusion method after 4 hr of incubation. (B) (◆) transfection by lipofectin; (□) simple dif-
fusion without any manipulation; (▲) conjugaton into streptolysin O (SL-O) with 100 IU/mL conc. and (○) with 1,000 IU/mL conc. AS-ODN
uptakes were increased sharply with time to 1 hr after incubation and maintained a plateau until 5 hr. Transfection by lipofectin treatments
was superior to other groups. Data represent mean+SD of these separate experiments.
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breakpoint specific, but there were no statistically significant
differences (Fig. 2).
Cytotoxic effects of various types of purging agents
measured by MTT assay 
We also used an MTT assay to measure the cytotoxic effects
of various kinds of AS-ODNs. As in cell count assay, in MTT
test, the cytotoxic effects of the AS-ODNs groups were also
superior to those of INF- groups (p<0.05). AS-ODNs in-
hibited the proliferation of K562 cells in a time-dependent
manner, especially the PS type, long chain and b3a2, but
there were no significant differences among various types of
AS-ODNs (Fig. 3). 
Cytotoxic effects of various types of purging agents
measured by clonogenic assay
The actual number of colony formation from 105 mononu-
clear K562 cells was 5,290±2,110 in the untreated control
group. Incubation with purging agents decreased the num-
ber of colonies significantly in all groups. As expected in the
AS-ODN group, a significant inhibition of CML clonogenic
cells was found.
Although INF- inhibited CML clonogenic cells, AS-ODN
was a more stronger inhibitor of CML cells. The recovery
rate of CFU-C as an untreated control was 64.0% in the
INF- group and 26.3% in the AS-ODNs (p<0.05). But
we could not find a morphologic variation of colony form
according to the purging agents (Fig. 4).
Inhibitory effects on the expression of bcr-abl mRNA
of various purging agents 
The effects of various AS-ODNs on the expression of bcr-abl
mRNA has been examined by RT-PCR. As shown in Fig. 5,
positive bands were abolished in AS-ODN groups, whereas
they were not inhibited in the INF- groups with RT-PCR
using bcr-abl primer and mRNA isolated from K562 cells.
Ex Vivo Purging Effects of Bcr-abl Antisense Oligodeoxynucleotide 187
Fig. 2. Cytotoxic effects of various purging agents measured by viable cell number. Viable cell numbers were decreased with time and
the peak effects were visible after 96 hr of incubation in all groups. The cytotoxic effects of the antisense oligodeoxyribonucleotides (AS-
ODNs) groups were superior to those of the interferon- (INF- ) groups (p<0.05) (A). Among AS-ODNs groups, cytotoxic effects were
higher in the phosphorothioate (PS) type (B), long chain type (C), and breakpoint specific b3a2 type (D), but there were no statistically
significant differences.
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K562 cells. However, treatment with AS-ODNs reduced
the bcr-abl mRNA expression. In particular, b3a2, (PS) type
showed the most profound effects (Fig. 5). 
DISCUSSION
AS-ODN directed to leukemia-specific transcripts has the
potential to specifically target the genes with a pathologic
role in leukemogenesis while sparing normal hematopoietic
cells. The use of bcr-abl AS-ODN may be considered one of
the newest approaches for the treatment of CML, and the in
vitro treatment before autograft, at the moment, appears to
be a clinical application more likely to produce favorable thera-
peutic outcomes (6).
Although leukemic cells take up AS-ODN more readily
than normal cells for AS-ODN in order to have a worthwhile
biologic effect, some means of enhancing cellular uptake is
essential (7). Therefore, we examined different strategies for
improving the effectiveness of AS-ODN uptake in CML cells
(8, 9). 
Liposome formation has been commonly used for effective
intracellular delivery of AS-OND. This kind of packaging
leads to the formation of micromolecular complexes with a
positive charge on the surface, permitting binding to the
negatively charged membrane. Following attachment to the
cell, the complexes are presumably taken up via endocytosis
(2, 4, 10, 11).  In the present study, we discerned that lipo-
some formation with lipofectin of AS-ODNs increased the
intracellular delivery of AS-ODN, achieving levels of approxi-
mately double. 
SL-O permeabilization was also enough to deliver AS-ODNs
into the cells. Especially SL-O permeabilization translates
into increased biologic effectiveness of AS-ODN in cells, as
evidenced by the decreased target mRNA levels (12, 13).
Although treatment with lipofectin resulted in higher intra-
cellular uptake of AS-ODNs than otherwise would have been
resulted from simple diffusion, simple diffusion method is
enough to deliver AS-ODNs to K562 cells. Furthermore,
diffusion is the easiest mode by which purging agents pass
across the biologic membrane in vitro. Taking all these into
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Fig. 3. Cytotoxic effects of various purging agents measured by MTT assay. In the MTT assay, the cytotoxic effects of antisense oligodeoxyri-
bonucleotides (AS-ODNs) groups were also superior to those of the interferon- (INF- ) groups (p<0.05) (A). AS-ODNs inhibited the prolif-
eration of K562 cells with time, particularly in phosphorothioate (PS) type (B), long chain type (C), and breakpoint-specific b3a2 type (D),
although there were no significant differences among the various types of AS-ODNs.
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ODNs into K562 cells.
The breakpoint of the Philadelphia chromosome in the
K562 cells is b3a2. Thus breakpoint specific AS-ODNs were
prepared for the b3a2 type (2, 3). Breakpoint-specific AS-
ODN may have a greater purging effectiveness than a non-
specific one. In our study, the breakpoint-specific AS-ODNs
of the b3a2 type show most effective purging effects than
nonspecific one although there were no statistically signifi-
cant differences.
The PO types of AS-ODNs are rapidly degraded in vivo
by the ubiquitously distributed DNases before they reach
their intracellular target RNA. Chemical modifications were
therefore made to increase their stability by protection against
enzymatic cleavage (14). The changes made in the chemical
structure of the AS-ODNs should not be associated with a
decrease in their RNA-binding ability. The most common
modified versions of AS-ODNs include the PS type, in which
one of the oxygens of the phosphate backbone is substituted
by a sulfuration. In mRNA expression of bcr-abl, we demon-
strated the differences between chemical structure of AS-
ODNs. The PS type is more effective than the PO type (15).
However, there were no differences between the PS and PO
types in the cell count assay and MTT methods.
The length of AS-ODNs is another factor of anti-tumor
effects of AS-ODNs. However, we could not find any differ-
ences according to the length using 18-mers and 24-mers.
There may be significant differences in the antitumor effects
if the size variation is greater (15).
The clonogenic activities of CML cells were reduced in the
AS-ODN b3a2 PS groups but not in the control and INF-
groups.
As expected, in methods of analysis, the AS-ODNs group
exhibited a superior purging effect to the INF group. There-
fore, AS-ODNs provide new anti-CML effects over conven-
tional chemotherapy (13). 
Gewirtz et al. first tried autologous transplantations in
CML patients with purged MNCs using AS-ODNs (16).
One of the problems associated with the systemic adminis-
tration of AS-ODNs in patients with CML may relate to the
nonspecific effects of these compounds and possible toxicity
toward normal marrow progenitors that could limit their use
as in vitro purging agents and as drugs for systemic therapy
(17). Additionally, due to the short living nature of AS-ODNs,
we should develop methods of more stable and sustained
inhibition of target genes. Moreover, further investigation
on the degradation kinetics and biological mechanisms of
AS-ODNs are needed further before clinical trials (14, 18).
The development of more specific and active AS-ODNs
and the optimization of in vitro and in vivo treatment con-
ditions may yield improved results in autografted CML
patients (19).
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